Name | Tagitanlimab |
---|
Description | Tagitanlimab (HBM-9167) is a humanized anti-PD-L1 antibody (IgG1κ type). Tagitanlimab selectively blocks the interaction of PD-L1 and PD-1. Tagitanlimab has the potential to be studied in recurrent or metastatic nasopharyngeal carcinoma (NPC)[1][2]. |
---|---|
Related Catalog | |
References |
[2]. Kaplon H, et al. Antibodies to watch in 2023. MAbs. 2023 Jan-Dec;15(1):2153410. |
No Any Chemical & Physical Properties |